508 related articles for article (PubMed ID: 18042936)
1. Projecting individualized absolute invasive breast cancer risk in African American women.
Gail MH; Costantino JP; Pee D; Bondy M; Newman L; Selvan M; Anderson GL; Malone KE; Marchbanks PA; McCaskill-Stevens W; Norman SA; Simon MS; Spirtas R; Ursin G; Bernstein L
J Natl Cancer Inst; 2007 Dec; 99(23):1782-92. PubMed ID: 18042936
[TBL] [Abstract][Full Text] [Related]
2. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.
Matsuno RK; Costantino JP; Ziegler RG; Anderson GL; Li H; Pee D; Gail MH
J Natl Cancer Inst; 2011 Jun; 103(12):951-61. PubMed ID: 21562243
[TBL] [Abstract][Full Text] [Related]
3. Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women.
Banegas MP; John EM; Slattery ML; Gomez SL; Yu M; LaCroix AZ; Pee D; Chlebowski RT; Hines LM; Thompson CA; Gail MH
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 28003316
[TBL] [Abstract][Full Text] [Related]
4. Validation of a breast cancer risk prediction model developed for Black women.
Boggs DA; Rosenberg L; Pencina MJ; Adams-Campbell LL; Palmer JR
J Natl Cancer Inst; 2013 Mar; 105(5):361-7. PubMed ID: 23411594
[TBL] [Abstract][Full Text] [Related]
5. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.
Chen J; Pee D; Ayyagari R; Graubard B; Schairer C; Byrne C; Benichou J; Gail MH
J Natl Cancer Inst; 2006 Sep; 98(17):1215-26. PubMed ID: 16954474
[TBL] [Abstract][Full Text] [Related]
6. Prospective approach to breast cancer risk prediction in African American women: the black women's health study model.
Boggs DA; Rosenberg L; Adams-Campbell LL; Palmer JR
J Clin Oncol; 2015 Mar; 33(9):1038-44. PubMed ID: 25624428
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
8. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
McCaskill-Stevens W; Wilson J; Bryant J; Mamounas E; Garvey L; James J; Cronin W; Wickerham DL
J Natl Cancer Inst; 2004 Dec; 96(23):1762-9. PubMed ID: 15572758
[TBL] [Abstract][Full Text] [Related]
9. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
10. Re: Projecting individualized absolute invasive breast cancer risk in African American women.
Levine BR
J Natl Cancer Inst; 2008 May; 100(9):683-4; author reply 684. PubMed ID: 18445823
[No Abstract] [Full Text] [Related]
11. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Freedman AN; Graubard BI; Rao SR; McCaskill-Stevens W; Ballard-Barbash R; Gail MH
J Natl Cancer Inst; 2003 Apr; 95(7):526-32. PubMed ID: 12671020
[TBL] [Abstract][Full Text] [Related]
12. National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N
Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
14. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
15. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
16. Prospective breast cancer risk prediction model for women undergoing screening mammography.
Barlow WE; White E; Ballard-Barbash R; Vacek PM; Titus-Ernstoff L; Carney PA; Tice JA; Buist DS; Geller BM; Rosenberg R; Yankaskas BC; Kerlikowske K
J Natl Cancer Inst; 2006 Sep; 98(17):1204-14. PubMed ID: 16954473
[TBL] [Abstract][Full Text] [Related]
17. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of breast cancer.
Thomsen A; Kolesar JM
Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
[TBL] [Abstract][Full Text] [Related]
19. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
[TBL] [Abstract][Full Text] [Related]
20. Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older.
Schonberg MA; Li VW; Eliassen AH; Davis RB; LaCroix AZ; McCarthy EP; Rosner BA; Chlebowski RT; Rohan TE; Hankinson SE; Marcantonio ER; Ngo LH
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26625899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
